{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:17:43Z","timestamp":1782569863923,"version":"3.54.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"No funding was granted"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12016-016-8585-0","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T02:35:45Z","timestamp":1474943745000},"page":"412-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of Treatment of Non-hereditary Angioedema"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-2231","authenticated-orcid":false,"given":"Mignon","family":"van den Elzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F. C. L.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Knulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Blankestijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van Os-Medendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G.","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"8585_CR1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","volume":"69","author":"T Zuberbier","year":"2014","unstructured":"Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al (2014) The EAACI\/GA(2) LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69:868\u2013887","journal-title":"Allergy"},{"key":"8585_CR2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/all.12380","volume":"69","author":"M Cicardi","year":"2014","unstructured":"Cicardi M, Aberer W, Banerji A, Ba\u015f M, Bernstein JA, Bork K et al (2014) Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69:602\u2013616","journal-title":"Allergy"},{"key":"8585_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13601-015-0049-8","volume":"5","author":"KJG Schulkes","year":"2015","unstructured":"Schulkes KJG, Van den Elzen MT, Hack EC, Otten HG, FM B-KCa, Knulst AC (2015) Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: a retrospective study. Clin Transl Allergy 5:5, eCollection","journal-title":"Clin Transl Allergy"},{"key":"8585_CR4","first-page":"1","volume":"65","author":"LM Lewis","year":"2014","unstructured":"Lewis LM, Graffeo C, Crosley P, Klausner HA, Clark CL, Frank A et al (2014) Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial. Ann Emerg Med 65:1\u201310","journal-title":"Ann Emerg Med"},{"key":"8585_CR5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","volume":"372","author":"M Ba\u015f","year":"2015","unstructured":"Ba\u015f M, Greve J, Stelter K, Havel M, Strassen U, Rotter N et al (2015) A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372:418\u2013425","journal-title":"N Engl J Med"},{"key":"8585_CR6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.annemergmed.2010.03.032","volume":"56","author":"M Ba\u015f","year":"2010","unstructured":"Ba\u015f M, Greve J, Stelter K, Bier H, Stark T, Hoffmann TK et al (2010) Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 56:278\u2013282","journal-title":"Ann Emerg Med"},{"key":"8585_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anai.2014.12.007","volume":"114","author":"JA Bernstein","year":"2015","unstructured":"Bernstein JA, Moellman JJ, Collins SP, Hart KW, Lindsell CJ (2015) Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. Ann Allergy Asthma Immunol 114:245\u2013249","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8585_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13601-015-0072-9","volume":"5","author":"K Weller","year":"2015","unstructured":"Weller K, Maurer M, Grattan C, Nakonechna A, Abuzakouk M, B\u00e9rard F et al (2015) ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin Transl Allergy 5:29","journal-title":"Clin Transl Allergy"},{"key":"8585_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, Gim\u00e9nez-Arnau A, Bousquet PJ, Bousquet J et al (2011) Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN Task Force report. Allergy Eur J Allergy Clin Immunol 66:317\u2013330","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"8585_CR10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh H-J, Saini S, Grattan C, Gimen\u00e9z-Arnau A et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924\u2013935","journal-title":"N Engl J Med"},{"key":"8585_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","volume":"128","author":"M Maurer","year":"2011","unstructured":"Maurer M, Altrichter S, Bieber T, Biedermann T, Br\u00e4utigam M, Seyfried S et al (2011) Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 128:202\u2013209.e5","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","volume":"128","author":"S Saini","year":"2011","unstructured":"Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A et al (2011) A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 128:567\u2013573.e1","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E et al (2013) Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132:101\u2013109","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, B\u00fclb\u00fcl Baskan E, Bradley MS et al (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135:67\u201375","journal-title":"J Invest Dermatol"},{"key":"8585_CR15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.13845","volume":"173","author":"MC Urgert","year":"2015","unstructured":"Urgert MC, van den Elzen MT, Knulst AC, Fedorowicz Z, van Zuuren EJ (2015) Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol 173:404\u2013415","journal-title":"Br J Dermatol"},{"key":"8585_CR16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006\u20131012","journal-title":"J Clin Epidemiol"},{"key":"8585_CR17","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). http:\/\/handbook.cochrane.org\/ . Accessed 4 Feb 2016"},{"key":"8585_CR18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/head.12246","volume":"53","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D (2013) The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 53:1541\u20131547","journal-title":"Headache"},{"key":"8585_CR19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/joim.12304","volume":"277","author":"M Mansi","year":"2015","unstructured":"Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R et al (2015) Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med 277:585\u2013593","journal-title":"J Intern Med"},{"key":"8585_CR20","first-page":"52","volume":"69","author":"L Bouillet","year":"2014","unstructured":"Bouillet L, Boccon-Gibod I, Launay D, Gompe A, Kanny G, Fain O (2014) Hereditary angioedema with normal C1 inhibitor in a French cohort: clinical characteristics and response to treatment with icatibant. Allergy 69:52\u201353 (Congress abstract)","journal-title":"Allergy"},{"key":"8585_CR21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11739-015-1205-9","volume":"10","author":"M Bova","year":"2015","unstructured":"Bova M, Guilarte M, Sala-Cunill A, Borrelli P, Rizzelli GML, Zanichelli A (2015) Treatment of ACEI-related angioedema with icatibant: a case series. Intern Emerg Med 10:345\u2013350","journal-title":"Intern Emerg Med"},{"key":"8585_CR22","doi-asserted-by":"crossref","first-page":"E198","DOI":"10.1002\/lary.25113","volume":"125","author":"J Greve","year":"2015","unstructured":"Greve J, Bas M, Hoffmann TK, Schuler PJ, Weller P, Kojda G et al (2015) Effect of C1-esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 125:E198\u2013E202","journal-title":"Laryngoscope"},{"key":"8585_CR23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jemermed.2012.07.055","volume":"44","author":"GW Hassen","year":"2013","unstructured":"Hassen GW, Kalantari H, Parraga M, Chirurgi R, Meletiche C, Chan C et al (2013) Fresh frozen plasma for progressive and refractory angiotensin-converting enzyme inhibitor-induced angioedema. J Emerg Med 44:764\u2013772","journal-title":"J Emerg Med"},{"key":"8585_CR24","doi-asserted-by":"crossref","first-page":"479.e1","DOI":"10.1016\/j.ajem.2014.08.055","volume":"33","author":"C Bartal","year":"2015","unstructured":"Bartal C, Zeldetz V, Stavi V, Barski L (2015) The role of icatibant\u2014the B2 bradykinin receptor antagonist\u2014in life-threatening laryngeal angioedema in the ED. Am J Emerg Med 33:479.e1\u2013e3","journal-title":"Am J Emerg Med"},{"key":"8585_CR25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ccr3.171","volume":"3","author":"SM Lipski","year":"2015","unstructured":"Lipski SM, Casimir G, Vanlommel M, Jeanmaire M, Dolhen P (2015) Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berinert\u00ae): about one case and review of the therapeutic arsenal. Clin Case Reports 3:126\u2013130","journal-title":"Clin Case Reports"},{"key":"8585_CR26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00134-014-3290-z","volume":"40","author":"A Charmillon","year":"2014","unstructured":"Charmillon A, Deibener J, Kaminsky P, Louis G (2014) Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibant. Intensive Care Med 40:893\u2013894","journal-title":"Intensive Care Med"},{"key":"8585_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/864815","volume":"2014","author":"NH Crooks","year":"2014","unstructured":"Crooks NH, Patel J, Diwakar L, Smith FG (2014) Icatibant in the treatment of angiotensin-converting enzyme inhibitor-induced angioedema. Case Reports Crit Care 2014:1\u20133","journal-title":"Case Reports Crit Care"},{"key":"8585_CR28","first-page":"1","volume":"2014","author":"ER Rasmussen","year":"2014","unstructured":"Rasmussen ER, Mey K, Bygum A (2014) Isolated oedema of the uvula induced by intense snoring and ACE inhibitor. BMJ Case Rep 2014:1\u20133","journal-title":"BMJ Case Rep"},{"key":"8585_CR29","first-page":"407","volume":"52","author":"C Yates","year":"2014","unstructured":"Yates, C, Cordeiro MC, Crespi M, Puiguriguer J (2014) Successful treatment of angiotensin-converting enzyme inhibitor angioedema with fresh frozen plasma. Clin Toxicol 52:407\u2013408 (Congress abstract)","journal-title":"Clin Toxicol"},{"key":"8585_CR30","first-page":"28","volume":"38","author":"BE Bledsoe","year":"2013","unstructured":"Bledsoe BE (2013) The swelling airway. Angioedema is not always caused by allergic reaction. JEMS 38:28\u201330","journal-title":"JEMS"},{"key":"8585_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-008295","author":"A Volans","year":"2013","unstructured":"Volans A, Ferguson R (2013) Using a bradykinin blocker in ACE inhibitor-associated angioedema in the emergency department. BMJ Case Rep. doi: 10.1136\/bcr-2012-008295","journal-title":"BMJ Case Rep"},{"key":"8585_CR32","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.jemermed.2011.03.029","volume":"43","author":"MR Bolton","year":"2012","unstructured":"Bolton MR, Dooley-Hash SL (2012) Angiotensin-converting enzyme inhibitor angioedema. J Emerg Med 43:e261\u2013e262","journal-title":"J Emerg Med"},{"issue":"30","key":"8585_CR33","first-page":"e1","volume":"2012","author":"M Gallitelli","year":"1664","unstructured":"Gallitelli M, Alzetta M (1664) Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med 2012(30):e1\u2013e2","journal-title":"Am J Emerg Med"},{"key":"8585_CR34","first-page":"826","volume":"109","author":"I Millot","year":"2012","unstructured":"Millot I, Plancade D, Hosotte M, Landy C, Nadaud J, Ragot C et al (2012) Tratment of a life-threatning laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates. Br J Anaesth 109:826\u2013827 (Congress abstract)","journal-title":"Br J Anaesth"},{"key":"8585_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006849","author":"M Stewart","year":"2012","unstructured":"Stewart M, McGlone R (2012) Fresh frozen plasma in the treatment of ACE inhibitor-induced angioedema. BMJ Case Rep. doi: 10.1136\/bcr-2012-006849","journal-title":"BMJ Case Rep"},{"key":"8585_CR36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00101-010-1798-3","volume":"60","author":"M Ba\u015f","year":"2011","unstructured":"Ba\u015f M, Kojda G, Stelter K (2011) \u201cAngiotensin-converting-enzyme\u201d\u2014Hemmer induziertes Angio\u00f6dem. Anaesthesist 60:1141\u20131145","journal-title":"Anaesthesist"},{"key":"8585_CR37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2010.03.023","volume":"63","author":"PW Schmidt","year":"2010","unstructured":"Schmidt PW, Hirschl MM, Trautinger F (2010) Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant. J Am Acad Dermatol 63:913\u2013914","journal-title":"J Am Acad Dermatol"},{"key":"8585_CR38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00101-007-1162-4","volume":"56","author":"MG Dehne","year":"2007","unstructured":"Dehne MG, Zimmer M, Deisz R, Bork K (2007) Angio\u00f6dem durch C1-esterase-inhibitor-mangel oder ACE-hemmer? Anaesthesist 56:335\u2013338","journal-title":"Anaesthesist"},{"key":"8585_CR39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1399-6576.2005.00819.x","volume":"50","author":"EW Nielsen","year":"2006","unstructured":"Nielsen EW, Gramstad S (2006) Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 50:120\u2013122","journal-title":"Acta Anaesthesiol Scand"},{"key":"8585_CR40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1067\/mai.2002.121313","volume":"109","author":"MY Karim","year":"2002","unstructured":"Karim MY, Masood A (2002) Fresh frozen plasma as a treatment for life-threatning ACE-inhibitor angioedema. J Allergy Clin Immunol 109:370\u2013371","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR41","first-page":"149","volume":"19","author":"G Bertazzoni","year":"2015","unstructured":"Bertazzoni G, Bresciani E, Cipollone L, Fante E, Galandrini R (2015) Treatment with icatibant in the management of drug induced angioedema. Eur Rev Med Pharmacol Sci 19:149\u2013153","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"8585_CR42","doi-asserted-by":"crossref","first-page":"AB38","DOI":"10.1016\/j.jaci.2013.12.161","volume":"133","author":"A Nanda","year":"2014","unstructured":"Nanda A, Wasan AN (2014) Ecallantide in treatment of type III hereditary angioedema. J Allergy Clin Immunol 133:AB38","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR43","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaip.2014.05.006","volume":"2","author":"MC Stahl","year":"2014","unstructured":"Stahl MC, Harris CK, Matto S, Bernstein JA (2014) Idiopathic nonhistaminergic angioedema successfully treated with ecallantide, icatibant, and C1 esterase inhibitor replacement. J Allergy Clin Immunol Pract 2:818\u2013819","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8585_CR44","doi-asserted-by":"crossref","first-page":"1295.e5","DOI":"10.1016\/j.ajem.2013.04.024","volume":"31","author":"V Montinaro","year":"2013","unstructured":"Montinaro V, Loizzo G, Zito A, Castellano G, Gesualdo L (2013) Successful treatment of a facial attack of angioedema with icatibant in a patient with idiopathic angioedema. Am J Emerg Med 31:1295.e5\u20136","journal-title":"Am J Emerg Med"},{"key":"8585_CR45","first-page":"bcr2013009616","volume":"2013","author":"AW O\u2019Keefe","year":"2013","unstructured":"O\u2019Keefe AW, McCusker C, Ben-Shoshan M (2013) Critical upper airway obstruction in sporadic angioedema responding to C1-esterase inhibitor. Case Rep 2013:bcr2013009616\u2013bcr2013009616","journal-title":"Case Rep"},{"key":"8585_CR46","volume-title":"Treatment of idiopathic nonhistaminergic angioedema with icatibant","author":"R Lleonart","year":"2012","unstructured":"Lleonart R, Andres B, Jacob J, Pasto L (2012) Treatment of idiopathic nonhistaminergic angioedema with icatibant"},{"key":"8585_CR47","doi-asserted-by":"crossref","first-page":"A77","DOI":"10.1016\/j.anai.2012.05.004","volume":"109","author":"SS Weiler CR","year":"2012","unstructured":"Weiler CR SS (2012) A case report of bradykinin receptorantagonist use in idiopathic non-histaminergic angioedema. Ann Allergy Asthma Immunol 109:A77","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8585_CR48","first-page":"280","volume":"24","author":"C Vela Vizcaino","year":"2014","unstructured":"Vela Vizcaino C, Sola Enrique L, Chugo Gordillo S, Lizaso Bacaicoa MT, Caballero Molina T, Garc\u00eda Figueroa BE (2014) Bradykinin-mediated hereditary angioedema (non-estrogen-dependant) without C1 inhibitor deficiency. J Investig Allergol Clin Immunol 24:280\u2013281","journal-title":"J Investig Allergol Clin Immunol"},{"key":"8585_CR49","first-page":"529","volume":"22","author":"C Col\u00e1s","year":"2012","unstructured":"Col\u00e1s C, Montoiro R, Fraj J, Garc\u00e9s M, Cubero J, Caballero T (2012) Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J Investig Allergol Clin Immunol 22:529\u2013531","journal-title":"J Investig Allergol Clin Immunol"},{"key":"8585_CR50","doi-asserted-by":"crossref","first-page":"AB40","DOI":"10.1016\/j.jaci.2013.12.168","volume":"1","author":"M Seoane","year":"2014","unstructured":"Seoane M, Caralli ME, Micozzi S, Rodriguez-Mazariego ME, Baeza ML (2014) Incidence and treatment of angioedema in a third level Spanish hospital. J Allergy Clin Immunol 1:AB40 (Congress abstract)","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006646","author":"EJ Illing","year":"2012","unstructured":"Illing EJ, Kelly S, Hobson JC, Charters S (2012) Icatibant and ACE inhibitor angioedema. BMJ Case Rep. doi: 10.1136\/bcr-2012-006646","journal-title":"BMJ Case Rep"},{"key":"8585_CR52","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/imj.12281","volume":"43","author":"YD Tran","year":"2013","unstructured":"Tran YD, de Malmanche T (2013) Management dilemmas in a case of angioedema with normal C1 inhibitor function during pregnancy. Intern Med J 43:1259\u20131259","journal-title":"Intern Med J"},{"key":"8585_CR53","doi-asserted-by":"crossref","first-page":"AB117","DOI":"10.1016\/j.jaci.2013.12.436","volume":"133","author":"J Zazzali","year":"2014","unstructured":"Zazzali J, Rosen K, Bradley MS, Raimundo K (2014) Angioedema and angioedema management from Asteria I and Asteria II: phase III studies to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. J Allergy Clin Immunol 133:AB117 (Congress abstract)","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 97","key":"8585_CR54","first-page":"258","volume":"68","author":"Y Rijo Calderon","year":"2013","unstructured":"Rijo Calderon Y, Palao P, Prior N, Fiandor A, Lopez-Serrano MC, Olalde S et al (2013) Treatment with off-label omalizumab in chronic idiopathic histaminergic urticaria\u2014angioedema resistant to high doses of antihistamines. Allergy 68(Suppl 97):258 (Congress abstract)","journal-title":"Allergy"},{"key":"8585_CR55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/cei.12379","volume":"178","author":"C Wintenberger","year":"2014","unstructured":"Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY et al (2014) Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 178:112\u2013117","journal-title":"Clin Exp Immunol"},{"key":"8585_CR56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clim.2015.02.013","volume":"157","author":"D Firinu","year":"2015","unstructured":"Firinu D, Bafunno V, Vecchione G, Barca MP, Manconi PE, Santacroce R et al (2015) Characterization of patients with angioedema without wheals: the importance of F12 gene screening. Clin Immunol 157:239\u2013248","journal-title":"Clin Immunol"},{"key":"8585_CR57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cea.12055","volume":"43","author":"C Saule","year":"2013","unstructured":"Saule C, Boccon-Gibod I, Fain O, Kanny G, Plu-Bureau G, Martin L et al (2013) Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy 43:475\u2013482","journal-title":"Clin Exp Allergy"},{"key":"8585_CR58","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1398-9995.2009.02233.x","volume":"65","author":"A Du-Tanh","year":"2009","unstructured":"Du-Tanh A, Raison-Peyron N, Drouet C, Guillot B (2009) Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema. Allergy 65:792\u2013793","journal-title":"Allergy"},{"key":"8585_CR59","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0002-9343(99)00123-0","volume":"1999","author":"M Cicardi","year":"1999","unstructured":"Cicardi M, Bergamaschini L, Zingale LC, Gioffr\u00e9 D, Agostoni A (1999) Idiopathic nonhistaminergic angioedema. Am J Med 1999:650\u2013654","journal-title":"Am J Med"},{"key":"8585_CR60","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.anai.2015.02.007","volume":"114","author":"J Azofra","year":"2015","unstructured":"Azofra J, D\u00edaz C, Ant\u00e9para I, Ja\u00faregui I, Soriano A, Ferrer M (2015) Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol 114:418\u2013419e1","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8585_CR61","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2007.07.041","volume":"120","author":"MF Sands","year":"2007","unstructured":"Sands MF, Blume JW, Schwartz SA (2007) Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 120:977\u2013979","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR62","first-page":"253","volume":"24","author":"MT Elzen Van Den","year":"2014","unstructured":"Van Den Elzen MT, R\u00f6ckmann H, Sanders CJG, Bruijnzeel-Koomen CAFM, Knulst AC (2014) Behandeling van chronische urticaria met omalizumab. Ned Tijdschr voor Dermatologie en Venereol 24:253\u2013256","journal-title":"Ned Tijdschr voor Dermatologie en Venereol"},{"key":"8585_CR63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2010.02472.x","volume":"66","author":"A Groffik","year":"2011","unstructured":"Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P (2011) Omalizumab\u2014an effective and safe treatment of therapy resistant chronic spontaneous urticaria. Allergy Eur J Allergy Clin Immunol 66:302\u2013303","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"8585_CR64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1346-8138.2011.01473.x","volume":"39","author":"S B\u00fcy\u00fck\u00f6zt\u00fcrk","year":"2012","unstructured":"B\u00fcy\u00fck\u00f6zt\u00fcrk S, Gelincik A, Demirt\u00fcrk M, Kocaturk E, \u00c7olako\u01e7lu B, Dal M (2012) Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol 39:439\u2013442","journal-title":"J Dermatol"},{"key":"8585_CR65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2009.09538.x","volume":"162","author":"A Perez","year":"2010","unstructured":"Perez A, Woods A, Grattan CEH (2010) Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 162:191\u2013194","journal-title":"Br J Dermatol"},{"key":"8585_CR66","doi-asserted-by":"crossref","first-page":"368053","DOI":"10.1155\/2015\/368053","volume":"2015","author":"MN Ghazanfar","year":"2015","unstructured":"Ghazanfar MN, Thomsen SF (2015) Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep Med 2015:368053","journal-title":"Case Rep Med"},{"key":"8585_CR67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40257-014-0103-7","volume":"16","author":"S Wieder","year":"2015","unstructured":"Wieder S, Maurer M, Lebwohl M (2015) Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues. Am J Clin Dermatol 16:19\u201326","journal-title":"Am J Clin Dermatol"},{"key":"8585_CR68","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1177\/0960327113510539","volume":"33","author":"A Kutlu","year":"2014","unstructured":"Kutlu A, Karabacak E, Aydin E, Ozturk S, Bozkurt B (2014) A patient with steroids and antihistaminic drug allergy and newly occurred chronic urticaria angioedema: what about omalizumab? Hum Exp Toxicol 33:882\u2013885","journal-title":"Hum Exp Toxicol"},{"key":"8585_CR69","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5415\/apallergy.2012.2.1.76","volume":"2","author":"AB Ozturk","year":"2012","unstructured":"Ozturk AB, Kocaturk E (2012) Omalizumab in recurring larynx angioedema: a case report. Asia Pac Allergy 2:76\u201385","journal-title":"Asia Pac Allergy"},{"key":"8585_CR70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-7961-9-11","volume":"9","author":"I S\u00e1nchez-Mach\u00edn","year":"2011","unstructured":"S\u00e1nchez-Mach\u00edn I, Iglesias-Souto J, Franco A, Barrios Y, Gonzalez R, Matheu V (2011) T cell activity in successful treatment of chronic urticaria with omalizumab. Clin Mol Allergy 9:11","journal-title":"Clin Mol Allergy"},{"key":"8585_CR71","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00105-010-2045-1","volume":"61","author":"H Korkmaz","year":"2010","unstructured":"Korkmaz H, Eigelshoven S, Homey B (2010) Omalizumab bei therapierefrakt\u00e4rer chronischer Urtikaria mit Angio\u00f6dem. Hautarzt 61:828\u2013831","journal-title":"Hautarzt"},{"key":"8585_CR72","first-page":"677","volume":"11","author":"A Websky Von","year":"2013","unstructured":"Von Websky A, Reich K, Steinkraus V, Breuer K (2013) Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab. JDDG - J Ger Soc Dermatology 11:677\u2013678","journal-title":"JDDG - J Ger Soc Dermatology"},{"issue":"Suppl 92","key":"8585_CR73","first-page":"459","volume":"65","author":"B Suna","year":"2010","unstructured":"Suna B, Asli G, Ferhan O, Mustafa D, Sacide E, Bahattin C et al (2010) Successfull treatment of chronic idiopathic angioedema with omalizumab. Allergy 65(Suppl 92):459 (Congress abstract)","journal-title":"Allergy"},{"key":"8585_CR74","doi-asserted-by":"crossref","first-page":"A71","DOI":"10.1016\/j.anai.2013.05.003","volume":"111","author":"DK Bayer","year":"2013","unstructured":"Bayer DK, DeGuzman M, Hanson IC (2013) Non-complement deficiency angioedema responsive to C1-inhibitor replacement. Ann Allergy Asthma Immunol 111:A71 (Congress abstract)","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8585_CR75","first-page":"687","volume":"33","author":"SM Maggadottir","year":"2013","unstructured":"Maggadottir SM, Sullivan KE, Heimall J (2013) Case report of 2 patients with common variable immunodeficiency (CVID) and debilitating chronic urticaria\/angioedema (CUA). J Clin Immunol 33:687 (Congress abstract)","journal-title":"J Clin Immunol"},{"key":"8585_CR76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1517\/14656566.2016.1104300","volume":"17","author":"MA Wu","year":"2016","unstructured":"Wu MA, Zanichelli A, Mansi M, Cicardi M (2016) Current treatment options for hereditary angioedema due to C1 inhibitor deficiency. Expert Opin Pharmacother 17:27\u201340","journal-title":"Expert Opin Pharmacother"},{"key":"8585_CR77","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Banerji A, Bracho F, Malbr\u00e1n A, Rosenkranz B, Riedl M et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532\u2013541","journal-title":"N Engl J Med"},{"key":"8585_CR78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Levy RJ, Mcneil DL, Li HH, Ph D, Sheffer AL et al (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. NEJM 363:523\u2013531","journal-title":"NEJM"},{"key":"8585_CR79","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","volume":"124","author":"TJ Craig","year":"2009","unstructured":"Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtu\u0142owicz K et al (2009) Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124:801\u2013808","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0805538","volume":"363","author":"BL Zuraw","year":"2010","unstructured":"Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513\u2013522","journal-title":"N Engl J Med"},{"key":"8585_CR81","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaci.2010.07.021","volume":"126","author":"B Zuraw","year":"2010","unstructured":"Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S et al (2010) Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126:821\u2013827.e14","journal-title":"J Allergy Clin Immunol"},{"key":"8585_CR82","unstructured":"Canadian Agency For Drugs And Technologies In Health (2015) Treatment of angiotensin converting enzyme inhibitor-induced angioedema: guidelines (CADTH rapid response report: summary of abstracts). CADTH, Ottawa"},{"key":"8585_CR83","doi-asserted-by":"crossref","unstructured":"Faisant C, Boccon-Gibod I, Mansard C, Dumestre Perard C, Pralong P, Chatain C et al. (2016) Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clin Exp Immunol 185:81\u201385","DOI":"10.1111\/cei.12789"},{"key":"8585_CR84","unstructured":"Summary of product characteristics of omalizumab (Xolair\u00ae) 150 mg solution for injection. https:\/\/www.medicines.org.uk\/emc\/medicine\/24912 and http:\/\/www.novartispharma.nl\/pdf\/ib\/Xolair_150.pdf"},{"key":"8585_CR85","unstructured":"Netherlands Pharmacovigilance Centre Lareb; WHO Collaborating Centre for Pharmacovigilance in Education and Patient Reporting. http:\/\/www.lareb.nl\/"},{"key":"8585_CR86","unstructured":"Assessment Report Kalbitor (ecallantide), procedure no.: EMEA\/H\/C\/002200\/. European Medicines Agency, London, 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/human\/002200\/WC500122745.pdf"},{"key":"8585_CR87","unstructured":"Product Monograph PrCYKLOKAPRON* (tranexamic acid); Tranexamic acid tablets BP and tranexamic acid injection BP. http:\/\/www.pfizer.ca\/sites\/g\/files\/g10017036\/f\/201410\/Cyklokapron.pdf"},{"key":"8585_CR88","unstructured":"Summary of product characteristics of methotrexate 10 mg tablets. https:\/\/www.medicines.org.uk\/emc\/medicine\/12034"},{"key":"8585_CR89","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/all.12007","volume":"67","author":"K Weller","year":"2012","unstructured":"Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K et al (2012) Development and construct validation of the angioedema quality of life questionnaire. Allergy 67:1289\u20131298","journal-title":"Allergy"},{"key":"8585_CR90","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/all.12209","volume":"68","author":"K Weller","year":"2013","unstructured":"Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K et al (2013) Development, validation, and initial results of the Angioedema Activity Score. Allergy 68:1185\u20131192","journal-title":"Allergy"},{"key":"8585_CR91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jdv.13200","volume":"29","author":"K Weller","year":"2015","unstructured":"Weller K, Zuberbier T, Maurer M (2015) Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. J Eur Acad Dermatology Venereol 29:38\u201344","journal-title":"J Eur Acad Dermatology Venereol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-016-8585-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8585-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8585-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:12:27Z","timestamp":1718813547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-016-8585-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["8585"],"URL":"https:\/\/doi.org\/10.1007\/s12016-016-8585-0","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]}}}